Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Ausun Pharmaceutical Co Days Payable Chart
SHSE:603229 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Zhejiang Ausun Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Ausun Pharmaceutical Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhejiang Ausun Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Zhejiang Ausun Pharmaceutical Co's Days Payable falls into.
Zhejiang Ausun Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Ausun Pharmaceutical Co (SHSE:603229) has a Days Payable of 194.58 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors. This is 51% below median its historical median of 394.33. Over the past decade, Zhejiang Ausun Pharmaceutical Co's Days Payable has ranged from 287.78 to 547.71. According to the industry distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #209 out of 701 companies in the Biotechnology industry, placing it in the top 29.8%.
Is Zhejiang Ausun Pharmaceutical Co's Days Payable too high?
Zhejiang Ausun Pharmaceutical Co's current Days Payable of 194.58 is 51% below median its 10-year median of 394.33. Over the past 10 years, this metric has ranged from a low of 287.78 to a high of 547.71. The Biotechnology industry median Days Payable is 112.84. Zhejiang Ausun Pharmaceutical Co's value of 194.58 is 72.4% above this industry median. Based on the distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #209 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zhejiang Ausun Pharmaceutical Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Ausun Pharmaceutical Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #209 out of 701 companies for Days Payable. This puts Zhejiang Ausun Pharmaceutical Co in the upper half of its industry. The industry median Days Payable is 112.84. Zhejiang Ausun Pharmaceutical Co's value of 194.58 is 72.4% above this benchmark. Historically, Zhejiang Ausun Pharmaceutical Co's own Days Payable has ranged from 287.78 to 547.71 over the past decade. While the company's 10-year median is 394.33 vs. the industry median of 112.84, Zhejiang Ausun Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Ausun Pharmaceutical Co's current Days Payable of 194.58 is 72.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Ausun Pharmaceutical Co's current Days Payable is 194.58, which is 51% below median its own 10-year median of 394.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Ausun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co (SHSE:603229) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.24, compared to a current price of ¥8.61 — trading 15.9% below its estimated fair value. The current Days Payable is 194.58, which is 51% below median its 10-year median of 394.33 and 72.4% above the Biotechnology industry median of 112.84. Zhejiang Ausun Pharmaceutical Co's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zhejiang Ausun Pharmaceutical Co (SHSE:603229), the current Days Payable is 194.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥8.61 is trading 15.9% below its estimated GF Value™ of ¥10.24.
GuruFocus considers Zhejiang Ausun Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603229:
Days Payable: 194.58 (51% below median its 10-year median of 394.33)
GF Value™: ¥10.24 vs. price of ¥8.61 (15.9% below fair value)
Industry Position: 72.4% above the Biotechnology median (#209 of 701)
No single metric tells the full story. See the SHSE:603229 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Ausun Pharmaceutical Co Business Description
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
82GF Score
Get the complete analysis for SHSE:603229
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603229 has been successfully added to your 
